

***Amendments to the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-119 (cancelled).

Claim 120 (New).     An isolated polypeptide comprising amino acids -51 to 133 of SEQ ID NO:2.

Claim 121 (New).     The polypeptide of claim 120 which comprises amino acids -51 to 360 of SEQ ID NO:2.

Claim 122 (New).     The polypeptide of claim 120, wherein said polypeptide binds TRAIL.

Claim 123 (New).     The polypeptide of claim 120, wherein said polypeptide induces apoptosis.

Claim 124 (New).     The polypeptide of claim 120, which is produced by a recombinant host cell.

Claim 125 (New).     The polypeptide of claim 124, wherein said recombinant host cell is a eukaryotic cell.

Claim 126 (New). The polypeptide of claim 120, further comprising a heterologous polypeptide.

Claim 127 (New). The polypeptide of claim 126, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

Claim 128 (New). The polypeptide of claim 127, wherein said immunoglobulin Fc region is a human immunoglobulin Fc region.

Claim 129 (New). A pharmaceutical composition comprising the polypeptide of claim 120 and a carrier.

Claim 130 (New). An isolated polypeptide comprising amino acids 1-360 of SEQ ID NO:2.

Claim 131 (New). The polypeptide of claim 130, wherein said polypeptide binds TRAIL.

Claim 132 (New). The polypeptide of claim 130, wherein said polypeptide induces apoptosis.

Claim 133 (New). The polypeptide of claim 130, which is produced by a recombinant host cell.

Claim 134 (New). The polypeptide of claim 133, wherein said recombinant host cell is a eukaryotic cell.

Claim 135 (New). The polypeptide of claim 130, further comprising a heterologous polypeptide.

Claim 136 (New). The polypeptide of claim 135, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

Claim 137 (New). The polypeptide of claim 136, wherein said immunoglobulin Fc region is a human immunoglobulin Fc region.

Claim 138 (New). A pharmaceutical composition comprising the polypeptide of claim 130 and a carrier.

Claim 139 (New). An isolated polypeptide, which comprises at least 30 contiguous amino acids of SEQ ID NO:2.

Claim 140 (New). The polypeptide of claim 139, comprising at least 50 contiguous amino acids of SEQ ID NO:2.

Claim 141 (New). The polypeptide of claim 139, further comprising a heterologous polypeptide.

Claim 142 (New). The polypeptide of claim 141, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

Claim 143 (New). The polypeptide of claim 142, wherein said immunoglobulin Fc region is a human immunoglobulin Fc region.

Claim 144 (New). A pharmaceutical composition comprising the polypeptide of claim 139 and a carrier.